4-methyl-2-nitrophenyl trifluoromethanesulfonate | 195455-54-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methyl-2-nitrophenyl trifluoromethanesulfonate
• 英文别名: trifluoromethanesulfonic acid 4-methyl-2-nitrophenyl ester；4-Methyl-2-nitrophenyl trifluoromethanesulfonate；(4-methyl-2-nitrophenyl) trifluoromethanesulfonate
• CAS: 195455-54-0
• 化学式: C₈H₆F₃NO₅S
• 分子量: 285.201
• InChiKey: PJUPDNUBFUXJEN-UHFFFAOYSA-N

物化性质

• 沸点：
  347.2±42.0 °C(Predicted)
• 密度：
  1.593±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  97.6
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-methyl-2-nitrophenyl trifluoromethanesulfonate 在 copper(l) iodide 、 二氯双(三邻甲苯膦)合钯(II) 、 铁粉 、 溶剂黄146 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 0.5h， 生成
  参考文献：
  名称：

  Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores

  摘要：

  We report a SAR of non-steroidal glucocorticoid mimetics that utilize indoles as A-ring mimetics. Detailed SAR is discussed with a focus on improving PR and MR selectivity, GR agonism, and in vitro dissociation profile. SAR analysis led to compound (R)-33 which showed high PR and MR selectivity, potent agonist activity, and reduced transactivation activity in the MMTV and aromatase assays. The compound is equipotent to prednisolone in the LPS-TNF model of inflammation. In mouse CIA, at 30 mg/kg compound (R)-33 inhibited disease progression with an efficacy similar to the 3 mg/kg dose of prednisolone. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.018
• 作为产物：
  描述：

  对甲酚 在 nitronium tetrafluoborate 、 三乙胺 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 3.0h， 生成 4-methyl-2-nitrophenyl trifluoromethanesulfonate
  参考文献：
  名称：

  Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophores

  摘要：

  We report a SAR of non-steroidal glucocorticoid mimetics that utilize indoles as A-ring mimetics. Detailed SAR is discussed with a focus on improving PR and MR selectivity, GR agonism, and in vitro dissociation profile. SAR analysis led to compound (R)-33 which showed high PR and MR selectivity, potent agonist activity, and reduced transactivation activity in the MMTV and aromatase assays. The compound is equipotent to prednisolone in the LPS-TNF model of inflammation. In mouse CIA, at 30 mg/kg compound (R)-33 inhibited disease progression with an efficacy similar to the 3 mg/kg dose of prednisolone. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.018

文献信息

• Aqueous Titanium Trichloride Promoted Reductive Cyclization of <i>o</i> ‐Nitrostyrenes to Indoles: Development and Application to the Synthesis of Rizatriptan and Aspidospermidine
  作者：Shuo Tong、Zhengren Xu、Mathias Mamboury、Qian Wang、Jieping Zhu

  DOI：10.1002/anie.201505713

  日期：2015.9.28

  TiCl3 solution at room temperature afforded indoles through a formal reductive C(sp2)–H amination process. A range of functions such as halides (Cl, Br), carbonyl (ester, carbamate), cyano, hydroxy, and amino groups were tolerated. From β,β‐disubstituted o‐nitrostyrenes, 2,3‐disubstituted indoles were formed by a domino reduction/cyclization/migration process. Mild conditions, simple experimental procedure

  在室温下用TiCl 3水溶液处理邻硝基苯乙烯，通过正式的还原性C（sp 2）–H胺化过程获得了吲哚。可以耐受多种功能，例如卤化物（Cl，Br），羰基（酯，氨基甲酸酯），氰基，羟基和氨基。通过多米诺还原/环化/迁移过程，由β，β-二取代的邻-硝基苯乙烯形成2,3-二取代的吲哚。温和的条件，简单的实验程序，易于接近的起始原料以及良好至极佳的收率是目前转化的特征。该方法学被用作简明合成利扎曲普坦和正式全合成阿斯哌啶的关键步骤。
• ANTI-VIRAL COMPOUNDS
  申请人：Rockway W. Todd

  公开号：US20070232645A1

  公开（公告）日：2007-10-04

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这种化合物的组合物、与其他抗病毒或治疗剂一起配方或共同管理这种化合物的组合物、用于合成这种化合物的过程和中间体，以及使用这种化合物治疗HCV或其他病毒感染的方法。
• Anti-viral compounds
  申请人：Abbott Laboratories

  公开号：US07763731B2

  公开（公告）日：2010-07-27

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了一种有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。该发明还涉及包含这种化合物的组合物、与其他抗病毒或治疗剂共同配方或共同管理这种化合物的组合物、用于合成这种化合物的过程和中间体，以及使用这种化合物治疗HCV或其他病毒感染的方法。
• Anti-Viral Compounds
  申请人：Rockway Todd W.

  公开号：US20100256139A1

  公开（公告）日：2010-10-07

  Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

  本发明揭示了一些有效抑制丙型肝炎病毒（“HCV”）或其他病毒复制的化合物。本发明还涉及包含这些化合物的组合物，这些化合物与其他抗病毒或治疗剂的联合制剂或联合给药，用于合成这些化合物的过程和中间体，以及使用这些化合物治疗HCV或其他病毒感染的方法。
• Antiviral compounds
  申请人：Abbott Laboratories

  公开号：EP2345652A1

  公开（公告）日：2011-07-20

  The present invention is directed to the use of compounds effective in inhibiting replication of Hepatitis C virus ("HCV") or other viruses, tautomers of said compounds, or pharmaceutically acceptable salts of said compounds or tautomers, for the manufacture of a medicament for the treatment of HCV.

  本发明涉及使用能有效抑制丙型肝炎病毒（"HCV"）或其他病毒复制的化合物、所述化合物的同系物或所述化合物或同系物的药学上可接受的盐，制造治疗 HCV 的药物。